The purpose of the present invention is to provide a method for producing γδT cells with which it is possible to obtain a cell population including a large amount of γδT cells and including virtually no cells infected by human T-cell leukemia virus (HTLV) even when PBMCs derived from a person infected with HTLV are used as the cell source. A cell population including a large amount of γδT cells and including virtually no HTLV-1-infected cells is obtained by culturing after removing CD4-positive cells that express CD4 (referred to hereinafter as “CD4+ cells”) and CD8-positive cells that express CD8 (referred to hereinafter as “CD8+ cells”) from the PBMCs that are used as the cell source, or after removing cells that express αβT cell receptors (αβTCR) (referred to hereinafter as “αβT cells”), before expanding γδT cells.

Provided is a cell culture method including introducing a factor into cells in a cell culture vessel, and culturing the cells into which the factor has been introduced in the same cell culture vessel. Also provided is a mononuclear cell collection method including treating blood to prepare a treated blood from which erythrocytes have been at least partially removed, diluting the treated blood, causing sedimentation of mononuclear cells contained in the diluted treated blood, removing the supernatant from the diluted treated blood, and collecting the mononuclear cells.

Provided is an erythrocyte removal device 100 including a blood container 10 that holds blood and an erythrocyte removal vessel 11 that at least partially removes erythrocytes from blood.

Provided herein are ex vivo methods for the expansion of cord blood-derived natural killer cells and methods of their use. Examples of embodiments include stimulating mononuclear cells from cord blood in the presence of antigen presenting cells (APCs) and IL-2 and re-stimulating the cells with APCs to produce expanded NK cells. In specific embodiments, the method does not utilize human leukocyte antigen (HLA) matching.

The present disclosure provides methods of hematopoietic stem cell transplantation (HSCT). In particular, the present disclosure provides a method of HSCT using a combination of an in-vivo T-cell depletion method, with an ex-vivo method of γδ T cell expansion and as T cell depletion. The in-vivo T-cell depletion method depletes (in-vivo) the alloreactive T cells that would otherwise increase the risk of GvHD.

Provided herein are methods for identifying and treating cancers that are resistant to PARP inhibition. Methods for sensitizing cancers to a PARP inhibitor therapy are also provided. In some aspects. PARP inhibitor cancers are treated with a PARP inhibitor therapy in combination with a c-Met inhibitor therapy.

A method of treating or preventing a sickle cell disease in a subject in need thereof is disclosed. The method comprising: (a) transplanting immature hematopoietic cells into the subject; and (b) administering to the subject a therapeutically effective amount of an isolated population of non-GVHD inducing anti-third party cells comprising cells having a central memory T-lymphocyte (Tcm) phenotype, the cells being tolerance inducing cells and capable of homing to the lymph nodes following transplantation.

The present invention is directed to the use of microfluidics in the preparation of cells and compositions for therapeutic uses.

A method is disclosed for modifying a sheet-shaped cell culture containing at least two types of cells. The method includes soaking the sheet-shaped cell culture in a low nutrient isotonic solution; and changing a content ratio of the at least two cell types constituting the sheet-shaped cell culture.

Systems, devices and methods for automatic magnetic separation of magnetized targets in a biological sample are herein disclosed, where they comprise a magnetic field shield/barrier controllably operable to control the magnetic field in terms of reaching and attracting the magnetized targets within the biological sample.